SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2010.
Cash, cash equivalents, and short-term investments at September 30, 2010 were $303.3 million as compared to $396.2 million at December 31, 2009.
Revenue for the third quarter of 2010 increased to $37.9 million as compared to $10.2 million in the third quarter of 2009. The increase in revenue year over year is largely the result of the amortization of the $125 million milestone payment received from AstraZeneca in September 2009 under the partnership agreement for NKTR-118.
Total operating costs and expenses in the third quarter of 2010 were $44.2 million compared to $39.1 million in the third quarter 2009. The increase in total operating costs and expenses was primarily due to an increase in research and development expenses.
Research and development expenses were $27.7 million and increased by 20% in the third quarter of 2010 as compared to $23.0 million for the same quarter in 2009. General and administrative expense increased slightly to $10.2 million in the third quarter 2010 from $9.9 million in the third quarter of 2009.
“Nektar’s continued productivity in research and development has resulted in a deep pipeline of programs that range from those in preclinical research to those preparing for Phase 3,” said Howard W. Robin, President and Chief Executive Officer of Nektar. “With our Phase 2 data this year from our exciting oncology candidate, NKTR-102, and the preclinical data from our new opioid candidate, NKTR-181, we continue to demonstrate the value of Nektar’s proprietary polymer conjugate technology.”
Net loss for the third quarter ended September 30, 2010 decreased to $8.7 million or $0.09 per share
|SOURCE Nektar Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved